OcuSphere Therapeutics develops a modular synthetic virion platform for precise gene therapy delivery to photoreceptor cells. This platform offers customizable payload capacity and reduced immunogenicity, enabling the development of more effective treatments for inherited retinal diseases.
Funding
Funding not disclosed
Founders
Product
Problem
Inherited retinal diseases currently lack effective therapeutic options, leaving patients with limited treatment pathways. Existing gene therapy delivery systems often face challenges with payload capacity, immunogenicity, and scalable manufacturing, hindering the development of viable treatments.
Solution
OcuSphere Therapeutics is developing a modular synthetic virion platform designed for precise gene therapy delivery to photoreceptor cells. This platform offers customizable payload capacity, enabling the encapsulation of larger or multiple therapeutic genetic materials. Its synthetic nature allows for reduced immunogenicity and the potential for scalable, consistent manufacturing processes. The technology leverages an AI-driven genomic analysis tool, Evo 2, to optimize promoter regions for enhanced therapeutic precision and efficacy within retinal cells. This approach aims to provide a more accessible and effective gene therapy solution for inherited retinal diseases.
Target Audience
The primary target audience includes pharmaceutical companies and biotechnology firms specializing in gene therapy and ophthalmology, as well as researchers focused on inherited retinal diseases.
Features
- Modular synthetic virion design with distinct functional components for cargo protection, cell targeting, endosomal escape, and nuclear entry.
- Surface engineering capabilities to evade pre-existing neutralizing antibodies and minimize immune responses.
- Customizable payload capacity to accommodate larger or multiple therapeutic genetic constructs.
- Non-replicative synthetic constructs designed to reduce risks of insertional mutagenesis.
- AI-driven genomic analysis tool (Evo 2) for predicting and optimizing promoter regions in retinal cell DNA.
- Machine learning models trained on extensive retinal cell type data for enhanced delivery precision.
- Potential for scalable and consistent manufacturing with reduced batch-to-batch variability.